Can HER2 overexpression predict response to pegylated liposomal doxorubicin in metastatic breast cancer patients? [4]

Annals of Oncology

Volumn 16, Issue 3, 2005, Pages 516-517

  Fabi, Alessandra ^a   Ferretti, Gia ^a   Salesi, N ^a   Papaldo, P ^a   Carlini, P ^a   Ciccarese, M ^a   Di Cocco, B ^a   Cecere, F ^a   Nardoni, C ^a   Felici, A ^a   Cognetti, F ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CISPLATIN; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GEMCITABINE; PACLITAXEL; TRASTUZUMAB;

ADULT; AGED; BREAST CANCER; BREAST METASTASIS; CANCER GRADING; CANCER PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DATA ANALYSIS; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; LETTER; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

ADULT; AGED; ANTIBIOTICS, ANTINEOPLASTIC; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, ERBB-2; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 20144386647     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdi078     Document Type: Letter

References (5)

1. Fabi A, Papaldo P, Ciccarese M et al. Pegylated liposomal doxorubicin (PLD) and gemcitabine (G) in metastatic breast cancer (MBC) patients: a phase II study. Proc Am Soc Clin Oncol 2004; 23: 79 (Abstr 813).
2. Rivera E, Valero V, Arun B et al. Phase II study of pegylated liposomal doxorubicin in combination with gemcitabine, in patients with metastatic breast cancer. J Clin Oncol 2003; 21: 3249-3254.
3. Tsai CM, Chang KT, Chen JY et al. Cytotoxic effects of gemcitabine-containing regimens against human non-small cell lung cancer cell lines which express different levels of p185neu. Cancer Res 1996; 56: 794-801.
4. Colomer R, Llombart-Cussac A, Lluch A et al. Biweekly paclitaxel plus gemcitabine in advanced breast cancer: phase II trial and predictive value of HER2 extracellular domain. Ann Oncol 2004; 15: 201-206.
5. Mass R. The role of HER-2 expression in predicting response to therapy in breast cancer. Semin Oncol 2090; 27 (6 Suppl 11): 46-52.